Immuno-Oncology | Specialty

Dr. Apolo on Avelumab for Metastatic Urothelial Carcinoma

May 4th 2017

Andrea B. Apolo, MD, medical oncologist at the National Cancer Institute, chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses avelumab (Bavencio) in patients with metastatic urothelial carcinoma from the phase Ib JAVELIN solid tumor trial.

Biomarker Advances Continue to Drive Progress in NSCLC

May 3rd 2017

Siddhartha Devarakonda, MD, discusses the importance of testing for molecular markers in NSCLC, rare mutations, and what work lies ahead for the field of lung cancer.

Lead CheckMate-040 Investigator Discusses Nivolumab in HCC

May 2nd 2017

Bruno Sangro, MD, PhD, discusses the CheckMate-040 data and the future of immuno-oncology agents in HCC.

Dr. Siefker-Radtke on FDA Approval of Durvalumab in Bladder Cancer

May 2nd 2017

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses the FDA approval of the PD-L1 inhibitor durvalumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed on standard platinum‑based chemotherapy.

Expert Discusses Immunotherapy Potential in Ovarian Cancer

May 2nd 2017

Bradley J. Monk, MD, shares his insight on the potential of immunotherapy in ovarian cancer, as well as what promise it might hold in other gynecologic malignancies.

Dr. Gubens on Prevalence of EGFR/ALK/ROS1 and PD-L1 Expression in NSCLC

May 1st 2017

Matthew Gubens, MD, an assistant professor of thoracic oncology at the University of California San Francisco, discusses the prevalence of patients with non–small cell lung cancer (NSCLC) who harbor mutations in EGFR/ALK/ROS1 as well as PD-L1 expression.

Dr. Seiwert on Final Thoughts on Immunotherapy in Head and Neck Cancer

May 1st 2017

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some final opinions on immunotherapy agents in the landscape of head and neck cancer.

FDA Approves Durvalumab for Bladder Cancer

May 1st 2017

The FDA has granted an accelerated approval to the PD-L1 inhibitor durvalumab (Imfinzi) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Novel Agents for Multiple Myeloma

April 28th 2017

Emerging Combination Therapies for Myeloma

April 28th 2017

Therapy Choice at Myeloma Progression

April 28th 2017

Treatment for Relapsed/Refractory Multiple Myeloma

April 28th 2017

Patient Selection for Ixazomib in Myeloma

April 28th 2017

Proteasome Inhibitor Use in Myeloma

April 28th 2017

EU Approval of Ixazomib for Relapsed/Refractory Myeloma

April 28th 2017

Defining Progression in Multiple Myeloma

April 28th 2017

Early versus Late Response in Multiple Myeloma

April 28th 2017

Maintenance Therapy in Multiple Myeloma

April 28th 2017

Transplant Timing in Multiple Myeloma

April 28th 2017

Upfront Therapy for Myeloma; Impact on Choice at Relapse

April 28th 2017